J Pharmacol Exp Ther 319, 1355-1365, (2006). Katnik, C., Guerrero, W. R., Pennypacker, K. R., Herrera, Y., & Cuevas, J. View abstract in PubMed Post navigationPreviousPrevious post:The expression and functional characterization of sigma-1 receptors in breast cancer cell lines.NextNext post:Interactions between 3,4- methylenedioxymethamphetamine and sigma-1 receptors.Related PostsAnavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
